RHBC
TAK icon

R.H. Bluestein & Co’s Takeda Pharmaceutical TAK Stock Holding History

R.H. Bluestein & Co’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,068
Closed -$178K – 352
2019
Q2 		$178K Hold
10,068
– – 0.01% 308
2019
Q1 		$205K Buy
+10,068
New +$203K 0.01% 281

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

R.H. Bluestein & Co's TAK Position: Q3 2019 in Review

R.H. Bluestein & Co sold out of Takeda Pharmaceutical (TAK) in Q3 2019, closing a stake of 10,068 shares — an estimated $178K sold.

R.H. Bluestein & Co first reported a position in TAK in Q1 2019 and held it in 2 quarters. The position peaked at $205K in Q1 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

  • R.H. Bluestein & Co reported no remaining Takeda Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • R.H. Bluestein & Co sold 10,068 Takeda Pharmaceutical shares in Q3 2019, an estimated $178K.
  • R.H. Bluestein & Co first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 2 quarters.
  • R.H. Bluestein & Co's Takeda Pharmaceutical position peaked at $205K in Q1 2019.
  • 317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on R.H. Bluestein & Co's 13F filing for Q3 2019, filed 13 Nov 2019.